Refractory myelodysplastic/myeloproliferative neoplasm
Clinical trials for Refractory myelodysplastic/myeloproliferative neoplasm explained in plain language.
Never miss a new study
Get alerted when new Refractory myelodysplastic/myeloproliferative neoplasm trials appear
Sign up with your email to follow new studies for Refractory myelodysplastic/myeloproliferative neoplasm, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to shrink Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase 1/2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New pill targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The …
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study is for people with certain blood cancers (like acute myeloid leukemia) that have a specific genetic change called a FLT3 mutation. The cancers have either come back or not responded to prior treatment. The trial tests a combination of three drugs—azacitidine, venetocla…
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC